Amphastar Pharmaceuticals, Inc. Long-Term Debt, Maturity, after Year Five
Amphastar Pharmaceuticals, Inc. (AMPH) had Long-Term Debt, Maturity, after Year Five of $345.00 million as of 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2024-02-29
- 2023-12-31: Long-Term Debt, Maturity, after Year Five $345.00M.
- 2023-09-30: Long-Term Debt, Maturity, after Year Five $645.00M.
- 2021-12-31: Long-Term Debt, Maturity, after Year Five $7.44M.
- 2020-12-31: Long-Term Debt, Maturity, after Year Five $16.52M.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2023-12-31 | $345.00M 10-K · filed 2024-02-29 |
| 2023-09-30 | $645.00M 10-Q · filed 2023-11-08 |
| 2021-12-31 | $7.44M 10-K · filed 2022-03-11 |
| 2020-12-31 | $16.52M 10-K · filed 2021-03-15 |
| 2019-12-31 | $17.43M 10-K · filed 2020-03-16 |
| 2018-12-31 | $17.97M 10-K · filed 2019-03-15 |
| 2017-12-31 | $18.17M 10-K · filed 2018-03-14 |
| 2016-12-31 | $3.19M 10-K · filed 2017-03-15 |
| 2015-12-31 | $7.30M 10-K · filed 2016-03-15 |
| 2014-12-31 | $4.05M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |